| HOME >> BIOLOGY >> TECHNOLOGY |
The Company will maintain its global headquarters in Canada where it
will focus on Canadian marketing activities and development of a U.S.
marketing and reimbursement strategy for the ColonSentry(TM) test. GeneNews
will continue development and validation of the ColonSentry(TM) test to
support a CLIA submission and the operation of a centralized clinical
reference laboratory to serve the North American market from its global
headquarters. Scientific leadership and direction for research and
development activities that will be pursued by the Company's Asian
facilities and the development of a strategy to create a personalized
health management system based on the Sentinel Principle(TM) will also be
managed in the Company's global headquarters.
About GeneNews
--------------
GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews, visit http://www.genenews.com.
This press release contains forward-looking statements, which reflect
the Company's current expectations regarding future events. The
forward-looking statements involve risks and uncertainties. Act
'/>"/>
| SOURCE GeneNews Limited Copyright©2008 PR Newswire. All rights reserved |